Health
Regeneron halts trial of antibody treatment in seriously ill Covid patients – Financial Times
Drug hailed as coronavirus ‘cure’ by Donald Trump will still be studied in mild-to-moderate cases
Regeneron has stopped enrolling seriously ill Covid-19 patients in a clinical trial of the antibody treatment that US President Donald Trump has hailed as a “cure” for the disease.
Shares in Regeneron fell as much as 3 per cent after an independent data monitoring committee warned that the risks might outweigh the benefits for hospitalised patients on high levels of oxygen.
The move comes after Eli Lilly, which is also developing a Covid-19 antibody treatment, stopped its trial in hospitalised…
-
Noosa News17 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
General19 hours agoFirst home buyers score early access to deposit scheme
-
Noosa News18 hours agoForum responds to urgent homelessness issues in Nambour
-
General17 hours agoEnergy provider ENGIE to ‘correct’ electricity bills for thousands of South Australian customers